Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
Go back to Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1| (NASDAQ: BLTE) | Delayed: 155.55 -1.59 (1.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.14 | 52 Week High | $ | |||
| Open | $155.90 | 52 Week Low | $ | |||
| Day High | $159.40 | P/E | N/A | |||
| Day Low | $153.75 | EPS | $ | |||
| Volume | 104,581 | |||||
